G

Gemini Therapeutics

34 employees

Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.

Basic info

Industry

biotechnology

Sectors

Health Diagnostics

Biotechnology

Biopharma

Date founded

2015

Funding rounds raised

Total raised

$95M

from 14 investors over 14 rounds

G

Gemini Therapeutics raised $95M on February 8, 2021

Investors: Suvretta Capital Management LLC, OrbiMed Advisors, Foresite Capital, Lightstone Ventures, Atlas Venture, Wellington Management, Wu Capital （双湖资本） and DAFNA Capital Management, LLC

G

Gemini Therapeutics raised $43M on October 17, 2017

Investors: Atlas Venture, OrbiMed Advisors and Lightstone Ventures

G

Gemini Therapeutics raised $2M on April 19, 2016

Investors: Lightstone Ventures, OrbiMed Advisors and Atlas Venture